Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)

Suresh S. Ramalingam, Chandra P. Belani, Philip C. MacK, Everett E. Vokes, Jeffrey Longmate, Ramaswamy Govindan, Marianna Koczywas, S. Percy Ivy, David R. Gandara

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases